Cargando…

Evaluation of morbidity in Schistosoma mansoni-positive primary and secondary school children after four years of mass drug administration of praziquantel in western Kenya

BACKGROUND: World Health Organization guidelines recommend preventive chemotherapy with praziquantel to control morbidity due to schistosomiasis. The primary aim of this cross-sectional study was to determine if 4 years of annual mass drug administration (MDA) in primary and secondary schools lowere...

Descripción completa

Detalles Bibliográficos
Autores principales: Abudho, Bernard O., Guyah, Bernard, Ondigo, Bartholomew N., Ndombi, Eric M., Ireri, Edmund, Carter, Jennifer M., Riner, Diana K., Kittur, Nupur, Karanja, Diana M. S., Colley, Daniel G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296924/
https://www.ncbi.nlm.nih.gov/pubmed/32539826
http://dx.doi.org/10.1186/s40249-020-00690-7
_version_ 1783546924979191808
author Abudho, Bernard O.
Guyah, Bernard
Ondigo, Bartholomew N.
Ndombi, Eric M.
Ireri, Edmund
Carter, Jennifer M.
Riner, Diana K.
Kittur, Nupur
Karanja, Diana M. S.
Colley, Daniel G.
author_facet Abudho, Bernard O.
Guyah, Bernard
Ondigo, Bartholomew N.
Ndombi, Eric M.
Ireri, Edmund
Carter, Jennifer M.
Riner, Diana K.
Kittur, Nupur
Karanja, Diana M. S.
Colley, Daniel G.
author_sort Abudho, Bernard O.
collection PubMed
description BACKGROUND: World Health Organization guidelines recommend preventive chemotherapy with praziquantel to control morbidity due to schistosomiasis. The primary aim of this cross-sectional study was to determine if 4 years of annual mass drug administration (MDA) in primary and secondary schools lowered potential markers of morbidity in infected children 1 year after the final MDA compared to infected children prior to initial MDA intervention. METHODS: Between 2012 and 2016 all students in two primary and three secondary schools within three kilometers of Lake Victoria in western Kenya received annual mass praziquantel administration. To evaluate potential changes in morbidity we measured height, weight, mid-upper arm circumference, hemoglobin levels, abdominal ultrasound, and quality of life in children in these schools. This study compared two cross-sectional samples of Schistosoma mansoni egg-positive children: one at baseline and one at year five, 1 year after the fourth annual MDA. Data were analyzed for all ages (6–18 years old) and stratified by primary (6–12 years old) and secondary (12–18 years old) school groups. RESULTS: The prevalence of multiple potential morbidity markers did not differ significantly between the egg-positive participants at baseline and those at 5 years by Mann Whitney nonparametric analysis and Fisher’s exact test for continuous and categorical data, respectively. There was a small but significantly higher score in school-related quality of life assessment by year five compared to baseline by Mann Whitney analysis (P = 0.048) in 13–18 year olds where malaria-negative. However, anemia was not positively impacted by four annual rounds of MDA, but registered a significant negative outcome. CONCLUSIONS: We did not detect differences in morbidity markers measured in a population of those infected or re-infected after multiple MDA. This could have been due to their relative insensitivity or a failure of MDA to prevent morbidity among those who remain infected. High malaria transmission in this area and/or a lack of suitable methods to measure the more subtle functional morbidities caused by schistosomiasis could be a factor. Further research is needed to identify and develop well-defined, easily quantifiable S. mansoni morbidity markers for this age group.
format Online
Article
Text
id pubmed-7296924
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72969242020-06-16 Evaluation of morbidity in Schistosoma mansoni-positive primary and secondary school children after four years of mass drug administration of praziquantel in western Kenya Abudho, Bernard O. Guyah, Bernard Ondigo, Bartholomew N. Ndombi, Eric M. Ireri, Edmund Carter, Jennifer M. Riner, Diana K. Kittur, Nupur Karanja, Diana M. S. Colley, Daniel G. Infect Dis Poverty Research Article BACKGROUND: World Health Organization guidelines recommend preventive chemotherapy with praziquantel to control morbidity due to schistosomiasis. The primary aim of this cross-sectional study was to determine if 4 years of annual mass drug administration (MDA) in primary and secondary schools lowered potential markers of morbidity in infected children 1 year after the final MDA compared to infected children prior to initial MDA intervention. METHODS: Between 2012 and 2016 all students in two primary and three secondary schools within three kilometers of Lake Victoria in western Kenya received annual mass praziquantel administration. To evaluate potential changes in morbidity we measured height, weight, mid-upper arm circumference, hemoglobin levels, abdominal ultrasound, and quality of life in children in these schools. This study compared two cross-sectional samples of Schistosoma mansoni egg-positive children: one at baseline and one at year five, 1 year after the fourth annual MDA. Data were analyzed for all ages (6–18 years old) and stratified by primary (6–12 years old) and secondary (12–18 years old) school groups. RESULTS: The prevalence of multiple potential morbidity markers did not differ significantly between the egg-positive participants at baseline and those at 5 years by Mann Whitney nonparametric analysis and Fisher’s exact test for continuous and categorical data, respectively. There was a small but significantly higher score in school-related quality of life assessment by year five compared to baseline by Mann Whitney analysis (P = 0.048) in 13–18 year olds where malaria-negative. However, anemia was not positively impacted by four annual rounds of MDA, but registered a significant negative outcome. CONCLUSIONS: We did not detect differences in morbidity markers measured in a population of those infected or re-infected after multiple MDA. This could have been due to their relative insensitivity or a failure of MDA to prevent morbidity among those who remain infected. High malaria transmission in this area and/or a lack of suitable methods to measure the more subtle functional morbidities caused by schistosomiasis could be a factor. Further research is needed to identify and develop well-defined, easily quantifiable S. mansoni morbidity markers for this age group. BioMed Central 2020-06-15 /pmc/articles/PMC7296924/ /pubmed/32539826 http://dx.doi.org/10.1186/s40249-020-00690-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Abudho, Bernard O.
Guyah, Bernard
Ondigo, Bartholomew N.
Ndombi, Eric M.
Ireri, Edmund
Carter, Jennifer M.
Riner, Diana K.
Kittur, Nupur
Karanja, Diana M. S.
Colley, Daniel G.
Evaluation of morbidity in Schistosoma mansoni-positive primary and secondary school children after four years of mass drug administration of praziquantel in western Kenya
title Evaluation of morbidity in Schistosoma mansoni-positive primary and secondary school children after four years of mass drug administration of praziquantel in western Kenya
title_full Evaluation of morbidity in Schistosoma mansoni-positive primary and secondary school children after four years of mass drug administration of praziquantel in western Kenya
title_fullStr Evaluation of morbidity in Schistosoma mansoni-positive primary and secondary school children after four years of mass drug administration of praziquantel in western Kenya
title_full_unstemmed Evaluation of morbidity in Schistosoma mansoni-positive primary and secondary school children after four years of mass drug administration of praziquantel in western Kenya
title_short Evaluation of morbidity in Schistosoma mansoni-positive primary and secondary school children after four years of mass drug administration of praziquantel in western Kenya
title_sort evaluation of morbidity in schistosoma mansoni-positive primary and secondary school children after four years of mass drug administration of praziquantel in western kenya
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296924/
https://www.ncbi.nlm.nih.gov/pubmed/32539826
http://dx.doi.org/10.1186/s40249-020-00690-7
work_keys_str_mv AT abudhobernardo evaluationofmorbidityinschistosomamansonipositiveprimaryandsecondaryschoolchildrenafterfouryearsofmassdrugadministrationofpraziquantelinwesternkenya
AT guyahbernard evaluationofmorbidityinschistosomamansonipositiveprimaryandsecondaryschoolchildrenafterfouryearsofmassdrugadministrationofpraziquantelinwesternkenya
AT ondigobartholomewn evaluationofmorbidityinschistosomamansonipositiveprimaryandsecondaryschoolchildrenafterfouryearsofmassdrugadministrationofpraziquantelinwesternkenya
AT ndombiericm evaluationofmorbidityinschistosomamansonipositiveprimaryandsecondaryschoolchildrenafterfouryearsofmassdrugadministrationofpraziquantelinwesternkenya
AT ireriedmund evaluationofmorbidityinschistosomamansonipositiveprimaryandsecondaryschoolchildrenafterfouryearsofmassdrugadministrationofpraziquantelinwesternkenya
AT carterjenniferm evaluationofmorbidityinschistosomamansonipositiveprimaryandsecondaryschoolchildrenafterfouryearsofmassdrugadministrationofpraziquantelinwesternkenya
AT rinerdianak evaluationofmorbidityinschistosomamansonipositiveprimaryandsecondaryschoolchildrenafterfouryearsofmassdrugadministrationofpraziquantelinwesternkenya
AT kitturnupur evaluationofmorbidityinschistosomamansonipositiveprimaryandsecondaryschoolchildrenafterfouryearsofmassdrugadministrationofpraziquantelinwesternkenya
AT karanjadianams evaluationofmorbidityinschistosomamansonipositiveprimaryandsecondaryschoolchildrenafterfouryearsofmassdrugadministrationofpraziquantelinwesternkenya
AT colleydanielg evaluationofmorbidityinschistosomamansonipositiveprimaryandsecondaryschoolchildrenafterfouryearsofmassdrugadministrationofpraziquantelinwesternkenya